AmplexDiagnostics announces CE-IVD molecular diagnostic technology combining LAMP and CRISPR

AmplexDiagnostics has announced a CE-IVD molecular diagnostic technology combining LAMP amplification and CRISPR-based detection for potential European diagnostic applications.

The technology combines loop-mediated isothermal amplification with CRISPR-based sequence recognition, bringing together two molecular methods intended to support nucleic acid detection in diagnostic testing.

The announcement describes the platform as CE-IVD, but the specific assays, intended clinical uses, applicable European conformity framework and diagnostic performance figures were not established in the supplied summary and require confirmation before clinical claims are made.

Field	Content
Article Type	Approvals
Company	AmplexDiagnostics
Product Type	Molecular diagnostic technology
Technology	Combined LAMP and CRISPR detection
LAMP Definition	Loop-mediated isothermal amplification
CRISPR Application	Sequence-specific nucleic acid detection
Regulatory Designation Reported	CE-IVD
Regulatory Jurisdiction	Europe
Regulatory Authority	European conformity assessment framework; specific notified body not confirmed
Regulatory Status	CE-IVD described in company announcement; exact conformity documentation not independently confirmed
Specific Assays	Not specified in supplied summary
Intended Clinical Use	Not specified in supplied summary
Clinical Indications	Not confirmed in supplied summary
Analytical Performance	Not provided in supplied summary
Clinical Performance	Not provided in supplied summary
Applicable Regulatory Framework	Specific directive or regulation not confirmed in supplied summary
Announcement Date	21 October 2026
What Happened	AmplexDiagnostics announced a molecular diagnostic technology combining LAMP amplification with CRISPR-based detection and described it as CE-IVD.
Why It Matters	Combining isothermal amplification and sequence-specific detection could support development of molecular diagnostic assays if validated for defined clinical uses.
Potential Impact	The approach may offer additional technical options for diagnostic developers, subject to assay validation and regulatory conformity.
Key Takeaway	The announcement concerns a LAMP-CRISPR diagnostic technology described as CE-IVD; its exact authorised uses and performance claims remain unconfirmed.
What to Watch	Manufacturer conformity documentation, intended-use statements, assay performance data, product availability and clinical adoption.
Primary Source	AmplexDiagnostics announcement via WebDisclosure
Primary Source URL	https://www.webdisclosure.com/press-release/amplexdiagnostics-etr-new-innovative-molecular-technology-combination-lamp-crispr-as-ce-ivd-lyWhEd4qbhd
Relevant Date	21 October 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com